WO2004089352A3 - Pharmaceutical combination for the treatment of spasticity and/or pain - Google Patents

Pharmaceutical combination for the treatment of spasticity and/or pain Download PDF

Info

Publication number
WO2004089352A3
WO2004089352A3 PCT/HU2004/000032 HU2004000032W WO2004089352A3 WO 2004089352 A3 WO2004089352 A3 WO 2004089352A3 HU 2004000032 W HU2004000032 W HU 2004000032W WO 2004089352 A3 WO2004089352 A3 WO 2004089352A3
Authority
WO
WIPO (PCT)
Prior art keywords
spasticity
treatment
pain
pharmaceutical combination
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2004/000032
Other languages
French (fr)
Other versions
WO2004089352A2 (en
Inventor
Karoly Tihanyi
Pal Kocsis
Gyoergy Nemeth
Istvan Tarnawa
Balazs Dalmadi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Vegyeszeti Gyar RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/551,510 priority Critical patent/US20060199841A1/en
Priority to SI200430433T priority patent/SI1610785T1/en
Priority to PL04726223T priority patent/PL1610785T3/en
Priority to JP2006506245A priority patent/JP2006522786A/en
Priority to EA200501591A priority patent/EA007732B1/en
Priority to DK04726223T priority patent/DK1610785T3/en
Priority to DE602004008440T priority patent/DE602004008440T2/en
Priority to HR20070441T priority patent/HRP20070441T3/en
Application filed by Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Vegyeszeti Gyar RT
Priority to EP04726223A priority patent/EP1610785B1/en
Priority to YUP-2005/0738A priority patent/RS20050738A/en
Publication of WO2004089352A2 publication Critical patent/WO2004089352A2/en
Publication of WO2004089352A3 publication Critical patent/WO2004089352A3/en
Anticipated expiration legal-status Critical
Priority to NO20055254A priority patent/NO20055254L/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical combination for the treatment of spasticity and/or pain characterized by that the combination contains as active ingredient 70-95% w/w compound of formula (I), wherein R represents a methyl or ethyl group, and 5-30 % w/w dextromethorphan (chemical name: (+/-)-3-methoxi-17-methylmorphinan).
PCT/HU2004/000032 2003-04-09 2004-04-07 Pharmaceutical combination for the treatment of spasticity and/or pain Ceased WO2004089352A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DE602004008440T DE602004008440T2 (en) 2003-04-09 2004-04-07 PHARMACEUTICAL COMBINATION PREPARATION FOR THE TREATMENT OF SPASTICITY AND / OR PAIN
PL04726223T PL1610785T3 (en) 2003-04-09 2004-04-07 Pharmaceutical combination for the treatment of spasticity and/or pain
JP2006506245A JP2006522786A (en) 2003-04-09 2004-04-07 Drug combinations for the treatment of spasticity and / or pain
EA200501591A EA007732B1 (en) 2003-04-09 2004-04-07 Pharmaceutical composition for the treatment of spasticity and/or pain
DK04726223T DK1610785T3 (en) 2003-04-09 2004-04-07 Pharmaceutical combination for the treatment of spasticity and / or pain
HR20070441T HRP20070441T3 (en) 2003-04-09 2004-04-07 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CREMES AND / OR PAIN
EP04726223A EP1610785B1 (en) 2003-04-09 2004-04-07 Pharmaceutical combination for the treatment of spasticity and/or pain
US10/551,510 US20060199841A1 (en) 2003-04-09 2004-04-07 Pharmaceutical combination for the treatment of spasticity and/or pain
SI200430433T SI1610785T1 (en) 2003-04-09 2004-04-07 Pharmaceutical combination for the treatment of spasticity and/or pain
YUP-2005/0738A RS20050738A (en) 2003-04-09 2004-04-07 Pharmaceutical combination for the treatment of s pasticity and/or pain
NO20055254A NO20055254L (en) 2003-04-09 2005-11-08 Pharmaceutical combination for the treatment of spasticity and / or pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP0300929 2003-04-09
HU0300929A HUP0300929A3 (en) 2003-04-09 2003-04-09 Analgetic and/or muscle relaxant pharmaceutical composition

Publications (2)

Publication Number Publication Date
WO2004089352A2 WO2004089352A2 (en) 2004-10-21
WO2004089352A3 true WO2004089352A3 (en) 2004-12-16

Family

ID=90001682

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2004/000032 Ceased WO2004089352A2 (en) 2003-04-09 2004-04-07 Pharmaceutical combination for the treatment of spasticity and/or pain

Country Status (16)

Country Link
US (1) US20060199841A1 (en)
EP (1) EP1610785B1 (en)
JP (1) JP2006522786A (en)
AT (1) ATE370733T1 (en)
CY (1) CY1106903T1 (en)
DE (1) DE602004008440T2 (en)
DK (1) DK1610785T3 (en)
EA (1) EA007732B1 (en)
ES (1) ES2293245T3 (en)
HR (1) HRP20070441T3 (en)
HU (1) HUP0300929A3 (en)
NO (1) NO20055254L (en)
PL (1) PL1610785T3 (en)
PT (1) PT1610785E (en)
RS (1) RS20050738A (en)
WO (1) WO2004089352A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2357808T3 (en) * 2001-06-07 2011-04-29 Christine Dr. Sang TREATMENT OF NEUROPATHIC PAIN WITH ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTOR (NMDA).
US8262942B2 (en) 2008-02-07 2012-09-11 The George Washington University Hollow carbon nanosphere based secondary cell electrodes
TR201720289A2 (en) * 2017-12-13 2019-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tolperizon and Selective COX-2 Inhibitor Combinations
JP7169580B2 (en) * 2018-09-27 2022-11-11 株式会社Ｌｔｔバイオファーマ Pharmaceutical composition for treating fibrosis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5340779A (en) * 1976-09-21 1978-04-13 Nippon Kayaku Co Ltd Optically active tolpertisone, their preparation and pharmaceuticals containting the same
WO1989005642A1 (en) * 1987-12-22 1989-06-29 Ferkany John W Dextrorphan potentiator for anticonvulsant composition and method
WO1989005641A1 (en) * 1987-12-22 1989-06-29 Pontecorvo Michael J Dextromethorphan potentiator for anticonvulsant composition and method
WO1997004780A2 (en) * 1995-08-02 1997-02-13 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
WO1998007447A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
WO2000059508A1 (en) * 1999-04-01 2000-10-12 Sanochemia Pharmazeutika Ag Tolperison-containing, pharmaceutical preparation for oral administration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206248A (en) * 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
JP4097285B2 (en) * 1994-09-22 2008-06-11 リチャード・アラン・スミス Compositions useful in the manufacture of a medicament for the treatment of various stubborn diseases
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
DE10123129A1 (en) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterated 3-piperidinopropiophenones and medicinal products containing these compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5340779A (en) * 1976-09-21 1978-04-13 Nippon Kayaku Co Ltd Optically active tolpertisone, their preparation and pharmaceuticals containting the same
WO1989005642A1 (en) * 1987-12-22 1989-06-29 Ferkany John W Dextrorphan potentiator for anticonvulsant composition and method
WO1989005641A1 (en) * 1987-12-22 1989-06-29 Pontecorvo Michael J Dextromethorphan potentiator for anticonvulsant composition and method
WO1997004780A2 (en) * 1995-08-02 1997-02-13 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
WO1998007447A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
WO2000059508A1 (en) * 1999-04-01 2000-10-12 Sanochemia Pharmazeutika Ag Tolperison-containing, pharmaceutical preparation for oral administration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 197821, Derwent World Patents Index; Class B03, AN 1978-37512A, XP002300728 *

Also Published As

Publication number Publication date
DE602004008440T2 (en) 2008-05-21
EP1610785A2 (en) 2006-01-04
HUP0300929A3 (en) 2005-06-28
HUP0300929A2 (en) 2005-02-28
PL1610785T3 (en) 2008-01-31
US20060199841A1 (en) 2006-09-07
EP1610785B1 (en) 2007-08-22
CY1106903T1 (en) 2012-09-26
DK1610785T3 (en) 2007-10-22
HUP0300929D0 (en) 2003-06-28
NO20055254L (en) 2006-01-06
JP2006522786A (en) 2006-10-05
NO20055254D0 (en) 2005-11-08
WO2004089352A2 (en) 2004-10-21
EA007732B1 (en) 2006-12-29
ATE370733T1 (en) 2007-09-15
PT1610785E (en) 2007-09-10
HRP20070441T3 (en) 2007-10-31
RS20050738A (en) 2008-04-04
ES2293245T3 (en) 2008-03-16
DE602004008440D1 (en) 2007-10-04
EA200501591A1 (en) 2006-06-30

Similar Documents

Publication Publication Date Title
TWI328576B (en) Diketohydrazine derivative compound, medicament containing same as active ingredient
TW200615266A (en) Organic compounds
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
WO2005018557A3 (en) Substituted pyridinones
MXPA04005456A (en) Acetylene derivatives having mglur 5 antagonistic activity.
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
WO2004005286A3 (en) Viral inhibitors
UA85708C2 (en) Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases
WO2004037789A8 (en) Methylene urea derivatives as raf-kinase inhibitors
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
WO2003101382A3 (en) Compounds useful in the treatment of anthrax and inhibiting lethal factor
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders
YU44202A (en) Quaternary salts of n-substituted cyclic or acyclic amines as pharmaceuticals
WO2005085236A3 (en) Caspase inhibitors and uses thereof
PL1610785T3 (en) Pharmaceutical combination for the treatment of spasticity and/or pain
SI1970372T1 (en) Salts of 9-oxoacridine-10-acetic acid with 1-alkylamno-1-desoxy-polyols
WO2001089282A3 (en) 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
AU2003256108A1 (en) Organic acid salt of amlodipine
WO2003086412A3 (en) Polyphosphonate derivatives for toothpaste compositions
WO2004072037A8 (en) 2,3'-bipyridines derivatives as selective cox-2 inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004726223

Country of ref document: EP

Ref document number: P-2005/0738

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: 10551510

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006506245

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200501591

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2004726223

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 10551510

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2004726223

Country of ref document: EP